Propanc Biopharma, a development‑stage biopharmaceutical company, has announced the launch of a Phase 1b first‑in‑human dose‑finding study for its lead proenzyme therapy, PRP. The study will enroll 30–40 patients with advanced solid tumors and is slated to begin in 2026 at a leading research center such as the Peter MacCallum Cancer Centre. PRP is an intravenous formulation that combines trypsinogen and chymotrypsinogen to target cancer stem cells, inhibit epithelial‑mesenchymal transition, and potentially enhance chemosensitivity. The company’s preclinical data show over 85 % tumor‑growth inhibition in pancreatic ductal adenocarcinoma models, underscoring the therapy’s promise as a complementary or alternative treatment to existing chemotherapy regimens.
The announcement builds on PRP’s prior compassionate‑use experience, where the proenzyme was administered to a small cohort of patients under emergency protocols. This first‑in‑human trial marks the first formal clinical evaluation of the therapy’s safety and pharmacokinetics in a broader patient population. Propanc’s FDA orphan drug designation for pancreatic cancer, granted in 2017, provides regulatory incentives such as priority review and potential market exclusivity, positioning PRP favorably within a high‑unmet‑need market. The global pancreatic cancer treatment market is projected to reach $3.70 billion in 2026 and $10.25 billion by 2034, reflecting a growing demand for innovative therapies that can reduce toxicity and improve long‑term outcomes.
CEO James Nathanielsz emphasized the potential impact of PRP, stating that the therapy “could transform cancer care by targeting metastasis and offering meaningful advantages over existing therapies.” He added that the company is committed to advancing the pipeline and believes the clinical data will demonstrate the therapy’s ability to reprogram cancer cells toward natural cell death, thereby reducing side‑effects associated with conventional cytotoxic agents. The planned Phase 1b study will provide critical safety data and inform the design of subsequent Phase 2 proof‑of‑concept trials in pancreatic and ovarian cancers, where the unmet need remains substantial.
The move to initiate human trials represents a significant de‑risking milestone for Propanc. By demonstrating safety and tolerability in patients, the company can validate its preclinical findings, attract additional investment, and potentially secure partnerships or licensing agreements. The orphan designation and the projected market growth further strengthen the commercial case, suggesting that a successful therapy could capture a meaningful share of the expanding pancreatic cancer treatment market. Overall, the announcement signals a pivotal shift from preclinical research to clinical development, positioning Propanc to advance its oncology pipeline toward regulatory approval and market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.